Fumihiko Hayakawa, MD [clinicaltrials_resource:9144236d46ba8ab005becd5752696505]
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT00130195]High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT00131027]Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT00131053]
overall official [clinicaltrials_vocabulary:overall-official]
Fumihiko Hayakawa, MD [clinicaltrials_resource:9144236d46ba8ab005becd5752696505]
Bio2RDF identifier
9144236d46ba8ab005becd5752696505
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9144236d46ba8ab005becd5752696505
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
bun-hy@med.nagoya-u.ac.jp
last name [clinicaltrials_vocabulary:last-name]
Fumihiko Hayakawa, MD
role [clinicaltrials_vocabulary:role]
Study Director
identifier
clinicaltrials_resource:9144236d46ba8ab005becd5752696505
title
Fumihiko Hayakawa, MD
@en
type
label
Fumihiko Hayakawa, MD [clinicaltrials_resource:9144236d46ba8ab005becd5752696505]
@en